Publish in this journal
Journal Information
Vol. 70. Issue 9.
Pages 785-787 (September 2017)
Scientific letter
DOI: 10.1016/j.rec.2016.12.033
Full text access
Prognostic Implications of Functional Mitral Regurgitation in Patients With Heart Failure and Reduced Ejection Fraction
Impacto de la insuficiencia mitral funcional en el pronóstico de pacientes con insuficiencia cardiaca y fracción de eyección reducida
Visits
...
M. Dolores García-Cosío Carmenaa,
Corresponding author
mdgcosio@secardiologia.es

Corresponding author:
, Eulalia Roig Minguellb, Andreu Ferrero-Gregorib, Rafael Vázquez Garcíac, Juan Delgado Jiméneza, Juan Cincab, on behalf of the investigators of the REDINSCOR research network
a Servicio de Cardiología, Hospital Universitario 12 de Octubre, Madrid, Spain
b Servicio de Cardiología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
c Servicio de Cardiología, Hospital Puerta del Mar, Cádiz, Spain
This item has received
...
Visits
(Daily data update)
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (1)
Table. Cox and Fine-Gray Modelsa
Full Text
To the Editor,

Functional mitral regurgitation (FMR) occurs in 20% to 30% of patients with heart failure (HF) and reduced left ventricular ejection fraction (LVEF).1,2 In these patients, FMR increases left ventricular (LV) end-diastolic pressure, contributes to LV remodeling, increases pulmonary hypertension, and worsens right ventricular function, all of which are associated with poor prognosis in HF. The clinical course of FMR depends on the type of heart disease, although the factors that determine its onset and the treatment of choice remain unknown. Treatment options include cardiac resynchronization and transplantation, but in most patients with this condition, it is not cured.3 Percutaneous mitral valve repair has comparable outcomes to surgery for organic mitral regurgitation with reasonable LVEF.4 Observational studies indicate that percutaneous treatment is beneficial in FMR with reduced LVEF. While randomized study results (ClinicalTrials.govNCT01772108) are awaited, it would be interesting to identify the patient profile that could benefit from this treatment.

We present the data on FMR from the Spanish HF Research Network (REDINSCOR). From 2007 to 2011, 2507 patients with symptomatic HF were recruited in 18 hospitals.5 We selected patients with LVEF < 40% with no organic valve disease or hypertrophic cardiomyopathy. Patients were then divided according to whether they had significant FMR (sFMR) (grade II-IV) or nonsignificant FMR (nsFMR) (grade 0-I). The analyses were performed using SPSS 22 and STATA-13.6

The study included 1526 patients: most were male (78%) with a history of hypertension (65%) and overweight (body mass index, 28.4). Fifty-seven percent were in functional class III or IV with elevated natriuretic peptide levels despite optimal HF therapy (86% were receiving beta-blockers, 87% were receiving angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists, and 64% were receiving aldosterone antagonists). The etiology of ventricular dysfunction was mostly ischemic (57%). At the time of study inclusion, 530 patients (35%) had signs of decompensated HF.

Significant FMR was detected in 746 patients (47%). The group with sFMR had a higher frequency of left bundle branch block, left atrial dilatation, and left ventricular dilatation, and worse LVEF. In addition, at the time of inclusion, they had a higher prevalence of decompensated HF, with associated increased natriuretic peptides, hypotension, and renal failure. The variables independently associated with the presence of sFMR were male sex (odds ratio [OR], 0.34; 95% confidence interval [95%CI], 0.25-0.47; P < .001), body mass index (OR, 0.94; 95%CI, 0.91-0.97; P < .001), decompensated HF (OR, 1.33; 95%CI, 1.01-1.74; P = .042), LV diameter (OR, 1.04; 95%CI, 1.02-1.05; P < .001), left atrial diameter (OR, 1.05; 95%CI, 1.03-1.07; P < .001), blood sodium level (OR, 0.97; 95%CI, 0.94-1.00; P = .044), and elevated natriuretic peptides (OR = 1.57; 95%CI, 1.17-2.1; P = .003) (area under the curve, 0.70; 95%CI, 0.67-0.74).

Median survival was 3.4 years [interquartile range, 1.7-4.7]. Survival at 1, 3, and 5 years was 84.5%, 69.9%, and 58.5%. Prognosis was worse (Figure A) in patients with sFMR (cumulative survival at 1 year, 81.5% vs 87.1%; at 3 years, 64.9% vs 74.3%, and at 5 years, 52.7% vs 63.5%; P < .001) due to mortality from refractory HF.

Figure.

Kaplan-Meier curves. A: prognosis was worse in patients with sFMR (P < .001). B: patients with signs of decompensation (unstable) had lower survival independently of FMR severity. In stable patients, the presence of sFMR identified a group with intermediate prognosis (P < .001). FMR, functional mitral regurgitation; nsFMR, nonsignificant functional mitral regurgitation; sFMR, significant functional mitral regurgitation.

(0.25MB).

In the multivariable model, the variables that were independently associated with mortality were decompensated HF (hazard ratio [HR], 1.7; 95%CI, 1.32-2.13; P < .001), functional class III-IV (HR, 1.3; 95%CI, 1.01-1.67; P = .041), systolic blood pressure (HR, 0.99; 95%CI, 0.98-0.99; P = .01), LA size (HR, 1.02; 95%CI, 1.01-1.03; P = .001), anemia (HR, 1.34; 95%CI, 1.06-1.69; P = .013), glomerular filtration rate (HR, 0.99; 95%CI, 0.98-0.99; P < .001), elevated natriuretic peptides (HR, 1.88; 95%CI, 1.38-2.56; P < .001), blood sodium levels (HR, 0.97; 95%CI, 0.95-0.99; P = .038) and treatment with beta-blockers (HR, 0.51; 95%CI, 0.38-0.68; P < .001).

In stable patients without decompensated HF (n = 996), the presence of sFMR was independently associated with overall mortality, cardiac mortality, and mortality due to refractory HF (Table and Figure B). When FMR was included in the basic model, the integrated discrimination improvement index (added discrimination value due to increased sensitivity without compromising specificity) increased by 1.2% (P = .003) for all-cause mortality, 2% (P < .001) for cardiac mortality, and 2.5% (P < .001) for mortality due to refractory HF.

Table.

Cox and Fine-Gray Modelsa

  HR/sHR  95%CI  P  C-statistic 
All-cause mortality, HR        0.70 
Functional mitral regurgitation  1.54  1.14-2.08  .005   
Systolic blood pressure, mmHg  0.99  0.98-0.99  .008   
Left ventricular end-diastolic diameter, mm  1.02  1-1.03  .042   
Glomerular filtration rate,b mL/min/1.73 m2  0.99  0.98-0.99  .001   
Elevated natriuretic peptides  2.11  1.45-3.06  .001   
Beta-blocker therapy  0.50  0.33-0.76  .001   
Cardiac mortality, sHR        0.71 
Functional mitral regurgitation  1.90  1.36-2.68  < .001   
Systolic blood pressure, mmHg  0.99  0.98-0.99  .011   
Left atrial diameter, mm  1.02  1-1.04  .05   
Glomerular filtration rate,b mL/min/1.73 m2  0.99  0.98-0.99  < .001   
Elevated natriuretic peptides  2.16  1.40-3.34  < .001   
Mortality due to refractory HF, sHR        0.78 
Functional mitral regurgitation  2.11  1.32-3.39  .002   
Diastolic blood pressure, mmHg  0.98  0.96-0.98  .001   
Ejection fraction, %  0.95  0.92-0.98  .001   
Left atrial diameter, mm  1.03  1-1.06  .046   
Glomerular filtration rate,b mL/min/1.73 m2  0.98  0.97-0.99  < .001   
Elevated natriuretic peptides  1.97  1.05-3.68  .034   

95%CI, 95% confidence interval; HF, heart failure; HR, hazard ratio; sHR, sub-hazard ratio.

a

The competing events are noncardiac mortality and mortality not due to refractory HF.

b

Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.

In patients with reduced LVEF, FMR is a marker of poor prognosis, but its role in decision-making is undefined. This could be partly because FMR severity varies depending on the patient's clinical condition, and partly because performing longitudinal studies that correctly evaluate the role of FMR in each phase of the disease can be difficult. The benefit of reducing FMR severity in advanced HF is uncertain. However, it is possible that in a certain group of patients, the hemodynamic improvement associated with FMR reduction may promote positive remodeling, as can happen with cardiac resynchronization therapy.3 Our study is the first to analyze the role of the patient's clinical condition in the course of FMR. Our results suggest that stable patients could potentially benefit from a reduction in FMR severity via percutaneous repair, and it would be interesting to study the effects of the procedure in this patient group. Randomized prospective studies are needed.

FUNDING

This study was funded by the Red de Investigación Cardiovascular (Cardiovascular Research Network).

References
[1]
E. Agricola, A. Ielasi, M. Oppizzi, et al.
Long-term prognosis of medically treated patients with functional mitral regurgitation and left ventricular dysfunction.
Eur J Heart Fail., 11 (2009), pp. 581-587
[2]
A. Rossi, F.L. Dini, P. Faggiano, et al.
Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy.
Heart., 97 (2011), pp. 1675-1680
[3]
M. Sitges, B. Vidal, V. Delgado, et al.
Long-term effect of cardiac resynchronization therapy on functional mitral valve regurgitation.
Am J Cardiol., 104 (2009), pp. 383-388
[4]
T. Feldman, S. Kar, S. Elmariah, et al.
Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-Year results of EVEREST II.
J Am Coll Cardiol., 66 (2015), pp. 2844-2854
[5]
L. Alonso-Pulpón, X. Borrás, J. Brugada, et al.
Clinical and preclinical heart failure research network (REDINSCOR).
Rev Esp Cardiol., 61 (2008), pp. 76-81
[6]
J. Fine, R.J. Gray.
A proportional hazards model for the subdistribution of a competing risk.
J Am Stat Assoc., 94 (1999), pp. 496-509
Copyright © 2016. Sociedad Española de Cardiología
Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?